Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Policies to aid the adoption of personalized medicine

Nature Reviews Drug Discovery volume 13, pages 159–160 (2014)Cite this article

Subjects

Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. European Commission Working Document. [online], (2013).

  2. US Food and Drug Administration. [online], (2013).

  3. Maliepaard, M. et al. Nature Rev. Drug Discov. 12, 103–115 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.P. and C.N. are supported by the County of Salzburg and FP7-PIRSES- GA-2008-230661 or PMU-FFF-E-12/15/075.

Author information

Authors and Affiliations

  1. Institute for Pharmacology and Toxicology, Helga & Erich Kellerhals Laboratories for Novel Therapeutics, Center for Pharmacogenetics and Pharmacogenomics, Paracelsus Medical University, Strubergasse 21, Salzburg, 5020, Austria

    Charity Nofziger & Markus Paulmichl

  2. European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK

    Marisa Papaluca

  3. Mayo Clinic Center for Regenerative Medicine, Mayo Clinic, Rochester, 55995, Minnesota, USA

    Andre Terzic

  4. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, Philadelphia, 19107, USA

    Scott Waldman

Authors
  1. Charity Nofziger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marisa Papaluca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andre Terzic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott Waldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Paulmichl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marisa Papaluca, Andre Terzic or Scott Waldman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Further regulatory documents related to personalized medicine (PDF 61 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nofziger, C., Papaluca, M., Terzic, A. et al. Policies to aid the adoption of personalized medicine. Nat Rev Drug Discov 13, 159–160 (2014). https://doi.org/10.1038/nrd4257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4257

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research